Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51694 | 0.87 | — | — | |
| SCHEMBL240787 | 0.87 | — | — | |
| Boric Acid SCHEMBL30102650 | 0.82 | CYP2A6 (0.39) | CYP2A6ALOX12ALDH1A1TSHRHSD17B10 | |
| Bromide SCHEMBL29262820 | 0.81 | CYP2A6 (0.44) | CYP2A6ALOX12ALDH1A1TSHRHSD17B10 | |
| Formaldehyde SCHEMBL28853578 | 0.79 | CYP2A6 (0.41) | CYP2A6ALOX12ALDH1A1TSHRHSD17B10 | |
| Naphthalene SCHEMBL215802 | 0.77 | CYP2A6 (0.67) | CYP2A6ALOX12ALDH1A1TSHRHSD17B10 | |
| SCHEMBL29262819 | 0.77 | CYP2A6 (0.39) | CYP2A6ALOX12ALDH1A1TSHRHSD17B10 | |
| Acetic Acid SCHEMBL8196779 | 0.76 | CES2 (0.41) | CYP2A6ALDH1A1TSHRHSD17B10TDP1 | |
| Naphthalene SCHEMBL28499343 | 0.74 | CYP2A6 (0.61) | CYP2A6ALOX12ALDH1A1TSHRHSD17B10 | |
| SCHEMBL440327 | 0.73 | ALDH1A1 (0.42) | CYP2A6ALOX12ALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622134-B2 | Organic electroluminescent device, and electronic apparatus | HODOGAYA CHEMICAL CO., LTD. (JP) | 2026-05-05 | — | — | US | disclosed |
| US-20240179930-A1 | ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS | HODOGAYA CHEMICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| CN-117247362-B | Light conversion agent with asymmetric structure, light conversion adhesive film and preparation method thereof | 常州百佳年代薄膜科技股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117247362-A | Light conversion agent with asymmetric structure, light conversion adhesive film and preparation method thereof | 常州百佳年代薄膜科技股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-111133600-B | Compound for organic photoelectric element, organic photoelectric element and display device | 三星SDI株式会社 | 2023-11-21 | — | — | CN | disclosed |
| WO-2022191256-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC EQUIPMENT THEREFOR | 保土谷化学工業株式会社 | 2022-09-15 | — | — | WO | disclosed |
| US-9359393-B2 | Photoresponsive nucleic acid manufacturing method | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2016-06-07 | — | — | US | disclosed |
| EP-2655344-B1 | NOVEL PHENAZINE DERIVATIVES AND THEIR USE | UNIV CATHOLIQUE LOUVAIN (BE) | 2015-11-25 | — | — | EP | disclosed |
| US-9181265-B2 | Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2015-11-10 | — | — | US | disclosed |
| US-20150236265-A1 | INDENE-BASED COMPOUNDS AND ORGANIC LIGHT-EMITTING DEVICES COMPRISING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-08-20 | — | — | US | disclosed |
| US-7592363-B2 | Indazoles | WYETH (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20070232628-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-10-04 | — | — | US | disclosed |
| EP-1784400-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1773781-A2 | INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES | Wyeth (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1742924-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006023462-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006017384-A2 | INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES | WYETH (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030612-A1 | Indazoles useful in treating cardiovascular diseases | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
| WO-2005108376-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030612-A1 | Indazoles useful in treating cardiovascular diseases | NR1H2, NR1H3, CYP46A1 | CYP2A6 182/4885ALOX12 347/4885ALDH1A1 483/4885 |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | CYP2A6 2285/4885ALOX12 2451/4885ALDH1A1 2678/4885 |
| US-12622134-B2 | Organic electroluminescent device, and electronic apparatus | KCNN1, KCNN2, ITGA1 | CYP2A6 1953/4885ALOX12 1377/4885ALDH1A1 665/4885 |
| US-20070232628-A1 | Calcilytic Compounds | SOST, CALCB, CALCR | CYP2A6 4118/4885ALOX12 2836/4885ALDH1A1 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.